What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Multiple myeloma, Internal medicine, Bortezomib, Surgery and Proteasome inhibitor.
Robert Z. Orlowski has included themes like Transplantation, Pharmacology and Dexamethasone in his Multiple myeloma study.
The study incorporates disciplines such as Gastroenterology and Oncology in addition to Internal medicine.
His Oncology research incorporates elements of Elotuzumab, Clinical trial, Isatuximab and Hazard ratio.
His Bortezomib research is multidisciplinary, incorporating elements of Siltuximab, Receptor, Peripheral neuropathy and Combination therapy.
His biological study spans a wide range of topics, including Mitogen-activated protein kinase, Surgical oncology and Toxicity.
His most cited work include:
- A phase 2 study of bortezomib in relapsed, refractory myeloma. (2325 citations)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma (818 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Multiple myeloma, Internal medicine, Bortezomib, Oncology and Lenalidomide.
His study in Multiple myeloma is interdisciplinary in nature, drawing from both Hematopoietic stem cell transplantation, Cancer research, Pharmacology and Dexamethasone.
His research in Internal medicine intersects with topics in Gastroenterology and Surgery.
The concepts of his Bortezomib study are interwoven with issues in Proteasome inhibitor, Proteasome, Regimen and Refractory.
His Oncology research is multidisciplinary, incorporating perspectives in Clinical trial, Phases of clinical research, Refractory Multiple Myeloma, Daratumumab and Relapsed refractory.
His Lenalidomide research includes themes of Neutropenia, Tolerability, Thalidomide and Maintenance therapy.
He most often published in these fields:
- Multiple myeloma (63.41%)
- Internal medicine (59.26%)
- Bortezomib (37.04%)
What were the highlights of his more recent work (between 2018-2021)?
- Multiple myeloma (63.41%)
- Internal medicine (59.26%)
- Oncology (32.30%)
In recent papers he was focusing on the following fields of study:
His main research concerns Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Dexamethasone.
The various areas that Robert Z. Orlowski examines in his Multiple myeloma study include Cancer research, Randomized controlled trial and Maintenance therapy.
His research is interdisciplinary, bridging the disciplines of Gastroenterology and Internal medicine.
His Oncology research also works with subjects such as
- Newly diagnosed that intertwine with fields like Transplant ineligible,
- Bone marrow most often made with reference to Cancer.
Robert Z. Orlowski interconnects Standard of care and Phases of clinical research in the investigation of issues within Lenalidomide.
His Bortezomib study incorporates themes from Proteasome inhibitor and Regimen.
Between 2018 and 2021, his most popular works were:
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (282 citations)
- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial (97 citations)
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. (52 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Robert Z. Orlowski focuses on Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Bortezomib.
His Multiple myeloma research includes elements of Cancer research, Maintenance therapy, Transplantation and Proteasome.
His Oncology research is multidisciplinary, relying on both Relapsed refractory, Newly diagnosed, Isatuximab and Hazard ratio.
Robert Z. Orlowski works mostly in the field of Lenalidomide, limiting it down to topics relating to Standard of care and, in certain cases, Asymptomatic and MEDLINE.
His research integrates issues of Proteasome inhibitor, Regimen and Gastroenterology in his study of Bortezomib.
His work carried out in the field of Elotuzumab brings together such families of science as Ixazomib, Prior Therapy and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
